ORYZON receives European Medicines Agency approval to initiate a Phase II study of iadadem... 24/02/2026 Healthcare Innovative drugs Essential thrombocythemia is the most common type of myeloproliferative neoplasm (MPN) and is associated with an... Partners - Oryzon Genomics
Childhood Cancer Needs Greater Awareness and Stable Funding to Accelerate Innovative Thera... 15/02/2026 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies Marina Salmón, Head of Project Evaluation at the Scientific Foundation of the Spanish Association Against Cancer, a... AseBio - Fundación Científica de la Asociación Española Contra el Cáncer
Childhood Cancer Needs Greater Awareness and Stable Funding to Accelerate Innovative Thera... 15/02/2026 Fundación Científica de la Asociación Española Contra el Cáncer In Spain, around 1,500 cases of childhood cancer are diagnosed each year (1% of the total), making research more... AseBio - Fundación Científica de la Asociación Española Contra el Cáncer
ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadade... 09/02/2026 Healthcare Innovative drugs The study, led by Yale University, explore the combination with atezolizumab and radiation therapy. Partners - Oryzon Genomics
Biotechnology in the fight against cancer: from smart vectors to protein disorder as a the... 04/02/2026 Healthcare Innovative drugs Personalized medicine Advanced therapies Biotechnology makes it possible to identify specific biomarkers and translate this knowledge into more effective and... AseBio
Biotechnology in the fight against cancer: from smart vectors to protein disorder as a the... 04/02/2026 Biotechnology makes it possible to identify specific biomarkers and translate this knowledge into more effective and... AseBio
The 4th AseBio – TERAV – CIBER Forum examines how to boost value chains in advanced therap... 14/01/2026 Healthcare Innovative drugs Personalized medicine Advanced therapies Advanced therapies offer new therapeutic options for complex diseases and also represent a strategic asset due to their... AseBio
The 4th AseBio – TERAV – CIBER Forum examines how to boost value chains in advanced therap... 14/01/2026 Advanced therapies offer new therapeutic options for complex diseases and also represent a strategic asset due to their... AseBio
AseBio welcomes the European institutions’ decision to move forward with the EU pharmaceut... 17/12/2025 Healthcare Drug discovery Rare diseases Innovative drugs Advanced therapies Antibiotic resistance As this legislation has not been amended for more than two decades, we encourage the Commission to be more ambitious in... AseBio
How biotechnology is reshaping pharmaceutical manufacturing: key insights from Klinea’s ex... 11/12/2025 Healthcare Innovative drugs Biotechnology is rapidly transforming the pharmaceutical landscape—yet its industrialisation presents challenges that... Partners - Klinea Biotech & Pharma Engineering
